{"version":"1.0","type":"rich","provider_name":"Tech & Business","provider_url":"https://techandbusiness.org","title":"ByteDance's Anew Labs enters AI drug discovery with IL-17 inhibitor","author_name":"T&B Newswire · AI, Tech & Business, Startups","thumbnail_url":"https://media.thenextweb.com/2026/05/bytedance-anew-labs-ai-drug-discovery.avif","width":600,"height":400,"html":"<blockquote class=\"tb-newswire-embed\" style=\"max-width:600px;border-left:3px solid #22d3ee;padding:12px 16px;margin:0;font-family:-apple-system,system-ui,sans-serif;background:#09090b;border-radius:0 8px 8px 0;\">\n      <p style=\"margin:0 0 8px;font-size:10px;font-weight:600;letter-spacing:0.1em;color:#71717a;text-transform:uppercase;\">T&B NEWSWIRE · AI, Tech & Business, Startups</p>\n      <p style=\"margin:0 0 8px;font-size:18px;font-weight:700;line-height:1.3;color:#fff;\"><a href=\"https://techandbusiness.org/newswire/SKF7Uc4hD777mU6Q3m3ALy\" style=\"color:#fff;text-decoration:none;\">ByteDance's Anew Labs enters AI drug discovery with IL-17 inhibitor</a></p>\n      <p style=\"margin:0;font-size:14px;color:#a1a1aa;line-height:1.5;\">ByteDance's drug discovery unit Anew Labs presented its first AI-designed therapy at the American Association of Immunologists' annual meeting in Boston in mid-April. The data showed a small molecule ...</p>\n    </blockquote>"}